nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—Acute respiratory distress syndrome—Topotecan—cervical cancer	0.0172	0.156	CcSEcCtD
Crizotinib—Febrile neutropenia—Topotecan—cervical cancer	0.00748	0.0678	CcSEcCtD
Crizotinib—Neuralgia—Topotecan—cervical cancer	0.00647	0.0587	CcSEcCtD
Crizotinib—Interstitial lung disease—Topotecan—cervical cancer	0.00635	0.0577	CcSEcCtD
Crizotinib—CASK—Irinotecan—Topotecan—cervical cancer	0.0046	0.32	CbGdCrCtD
Crizotinib—Respiratory failure—Topotecan—cervical cancer	0.00458	0.0416	CcSEcCtD
Crizotinib—Pulmonary embolism—Topotecan—cervical cancer	0.0045	0.0408	CcSEcCtD
Crizotinib—IGF1R—Irinotecan—Topotecan—cervical cancer	0.00433	0.301	CbGdCrCtD
Crizotinib—Neuropathy—Topotecan—cervical cancer	0.00422	0.0383	CcSEcCtD
Crizotinib—Sepsis—Topotecan—cervical cancer	0.0039	0.0354	CcSEcCtD
Crizotinib—PTK2—Irinotecan—Topotecan—cervical cancer	0.00368	0.256	CbGdCrCtD
Crizotinib—Aspartate aminotransferase increased—Topotecan—cervical cancer	0.00294	0.0267	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Topotecan—cervical cancer	0.00288	0.0261	CcSEcCtD
Crizotinib—Neutropenia—Topotecan—cervical cancer	0.00264	0.0239	CcSEcCtD
Crizotinib—Pneumonia—Topotecan—cervical cancer	0.00253	0.023	CcSEcCtD
Crizotinib—Infestation NOS—Topotecan—cervical cancer	0.00252	0.0228	CcSEcCtD
Crizotinib—Infestation—Topotecan—cervical cancer	0.00252	0.0228	CcSEcCtD
Crizotinib—Neuropathy peripheral—Topotecan—cervical cancer	0.00247	0.0224	CcSEcCtD
Crizotinib—Hepatobiliary disease—Topotecan—cervical cancer	0.00238	0.0216	CcSEcCtD
Crizotinib—Hypoaesthesia—Topotecan—cervical cancer	0.00225	0.0204	CcSEcCtD
Crizotinib—Mediastinal disorder—Topotecan—cervical cancer	0.00204	0.0185	CcSEcCtD
Crizotinib—Malnutrition—Topotecan—cervical cancer	0.00197	0.0178	CcSEcCtD
Crizotinib—Anaemia—Topotecan—cervical cancer	0.00182	0.0165	CcSEcCtD
Crizotinib—AURKA—Irinotecan—Topotecan—cervical cancer	0.00178	0.124	CbGdCrCtD
Crizotinib—Leukopenia—Topotecan—cervical cancer	0.00176	0.016	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00166	0.0151	CcSEcCtD
Crizotinib—Infection—Topotecan—cervical cancer	0.00159	0.0145	CcSEcCtD
Crizotinib—Nervous system disorder—Topotecan—cervical cancer	0.00157	0.0143	CcSEcCtD
Crizotinib—Skin disorder—Topotecan—cervical cancer	0.00156	0.0141	CcSEcCtD
Crizotinib—Paraesthesia—Topotecan—cervical cancer	0.00144	0.0131	CcSEcCtD
Crizotinib—Dyspnoea—Topotecan—cervical cancer	0.00143	0.013	CcSEcCtD
Crizotinib—Dyspepsia—Topotecan—cervical cancer	0.00141	0.0128	CcSEcCtD
Crizotinib—Decreased appetite—Topotecan—cervical cancer	0.00139	0.0127	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Topotecan—cervical cancer	0.00139	0.0126	CcSEcCtD
Crizotinib—Fatigue—Topotecan—cervical cancer	0.00138	0.0126	CcSEcCtD
Crizotinib—Constipation—Topotecan—cervical cancer	0.00137	0.0125	CcSEcCtD
Crizotinib—Body temperature increased—Topotecan—cervical cancer	0.00127	0.0115	CcSEcCtD
Crizotinib—Asthenia—Topotecan—cervical cancer	0.00115	0.0104	CcSEcCtD
Crizotinib—Diarrhoea—Topotecan—cervical cancer	0.0011	0.00996	CcSEcCtD
Crizotinib—Dizziness—Topotecan—cervical cancer	0.00106	0.00963	CcSEcCtD
Crizotinib—Vomiting—Topotecan—cervical cancer	0.00102	0.00926	CcSEcCtD
Crizotinib—Rash—Topotecan—cervical cancer	0.00101	0.00918	CcSEcCtD
Crizotinib—Dermatitis—Topotecan—cervical cancer	0.00101	0.00917	CcSEcCtD
Crizotinib—Nausea—Topotecan—cervical cancer	0.000953	0.00865	CcSEcCtD
Crizotinib—RPS6KB1—endometrium—cervical cancer	0.000929	0.00213	CbGeAlD
Crizotinib—TYK2—mammalian vulva—cervical cancer	0.000927	0.00212	CbGeAlD
Crizotinib—PRKD3—lymph node—cervical cancer	0.000927	0.00212	CbGeAlD
Crizotinib—EPHA4—uterus—cervical cancer	0.000926	0.00212	CbGeAlD
Crizotinib—EPHB4—decidua—cervical cancer	0.000925	0.00212	CbGeAlD
Crizotinib—AURKA—vagina—cervical cancer	0.000924	0.00211	CbGeAlD
Crizotinib—FGR—endometrium—cervical cancer	0.000923	0.00211	CbGeAlD
Crizotinib—TESK1—female gonad—cervical cancer	0.000922	0.00211	CbGeAlD
Crizotinib—AXL—endometrium—cervical cancer	0.000919	0.0021	CbGeAlD
Crizotinib—JAK2—decidua—cervical cancer	0.000919	0.0021	CbGeAlD
Crizotinib—TESK1—vagina—cervical cancer	0.000916	0.0021	CbGeAlD
Crizotinib—IRAK1—mammalian vulva—cervical cancer	0.000915	0.0021	CbGeAlD
Crizotinib—EPHB4—renal system—cervical cancer	0.000909	0.00208	CbGeAlD
Crizotinib—MAP3K2—uterus—cervical cancer	0.000908	0.00208	CbGeAlD
Crizotinib—EPHA2—decidua—cervical cancer	0.000908	0.00208	CbGeAlD
Crizotinib—DSTYK—lymph node—cervical cancer	0.000905	0.00207	CbGeAlD
Crizotinib—JAK2—renal system—cervical cancer	0.000902	0.00207	CbGeAlD
Crizotinib—BMP2K—female reproductive system—cervical cancer	0.000899	0.00206	CbGeAlD
Crizotinib—RPS6KB1—mammalian vulva—cervical cancer	0.000898	0.00206	CbGeAlD
Crizotinib—MERTK—female gonad—cervical cancer	0.000897	0.00205	CbGeAlD
Crizotinib—BLK—lymph node—cervical cancer	0.000895	0.00205	CbGeAlD
Crizotinib—FGR—mammalian vulva—cervical cancer	0.000893	0.00204	CbGeAlD
Crizotinib—LCK—mammalian vulva—cervical cancer	0.000893	0.00204	CbGeAlD
Crizotinib—MERTK—vagina—cervical cancer	0.000891	0.00204	CbGeAlD
Crizotinib—PTK2—uterus—cervical cancer	0.000889	0.00204	CbGeAlD
Crizotinib—AXL—mammalian vulva—cervical cancer	0.000889	0.00204	CbGeAlD
Crizotinib—EPHB6—uterine cervix—cervical cancer	0.000888	0.00203	CbGeAlD
Crizotinib—MAP3K3—decidua—cervical cancer	0.000886	0.00203	CbGeAlD
Crizotinib—TEK—decidua—cervical cancer	0.000886	0.00203	CbGeAlD
Crizotinib—MAP4K5—decidua—cervical cancer	0.000886	0.00203	CbGeAlD
Crizotinib—SLK—endometrium—cervical cancer	0.000885	0.00203	CbGeAlD
Crizotinib—LTK—lymph node—cervical cancer	0.000884	0.00202	CbGeAlD
Crizotinib—CASK—lymph node—cervical cancer	0.000884	0.00202	CbGeAlD
Crizotinib—TYK2—uterus—cervical cancer	0.000884	0.00202	CbGeAlD
Crizotinib—EPHB4—endometrium—cervical cancer	0.000878	0.00201	CbGeAlD
Crizotinib—LIMK2—female gonad—cervical cancer	0.000877	0.00201	CbGeAlD
Crizotinib—NUAK2—female gonad—cervical cancer	0.000874	0.002	CbGeAlD
Crizotinib—JAK2—endometrium—cervical cancer	0.000872	0.002	CbGeAlD
Crizotinib—LIMK2—vagina—cervical cancer	0.000872	0.002	CbGeAlD
Crizotinib—TEK—renal system—cervical cancer	0.00087	0.00199	CbGeAlD
Crizotinib—NUAK2—vagina—cervical cancer	0.000868	0.00199	CbGeAlD
Crizotinib—PTK2B—female reproductive system—cervical cancer	0.000868	0.00199	CbGeAlD
Crizotinib—MAP3K12—female gonad—cervical cancer	0.000868	0.00199	CbGeAlD
Crizotinib—ACVR1—female gonad—cervical cancer	0.000868	0.00199	CbGeAlD
Crizotinib—FLT3—female gonad—cervical cancer	0.000868	0.00199	CbGeAlD
Crizotinib—MAP3K12—vagina—cervical cancer	0.000862	0.00197	CbGeAlD
Crizotinib—ACVR1—vagina—cervical cancer	0.000862	0.00197	CbGeAlD
Crizotinib—EPHA2—endometrium—cervical cancer	0.000862	0.00197	CbGeAlD
Crizotinib—RIPK2—female reproductive system—cervical cancer	0.000861	0.00197	CbGeAlD
Crizotinib—YES1—uterine cervix—cervical cancer	0.000858	0.00197	CbGeAlD
Crizotinib—MAPK7—lymph node—cervical cancer	0.000857	0.00196	CbGeAlD
Crizotinib—TXK—lymph node—cervical cancer	0.000857	0.00196	CbGeAlD
Crizotinib—SLK—mammalian vulva—cervical cancer	0.000856	0.00196	CbGeAlD
Crizotinib—STK10—uterine cervix—cervical cancer	0.000851	0.00195	CbGeAlD
Crizotinib—LCK—uterus—cervical cancer	0.00085	0.00195	CbGeAlD
Crizotinib—STK35—female gonad—cervical cancer	0.00085	0.00195	CbGeAlD
Crizotinib—EPHB4—mammalian vulva—cervical cancer	0.00085	0.00195	CbGeAlD
Crizotinib—FES—lymph node—cervical cancer	0.000848	0.00194	CbGeAlD
Crizotinib—TAOK3—uterine cervix—cervical cancer	0.000847	0.00194	CbGeAlD
Crizotinib—AXL—uterus—cervical cancer	0.000847	0.00194	CbGeAlD
Crizotinib—EPHB6—decidua—cervical cancer	0.000846	0.00194	CbGeAlD
Crizotinib—STK35—vagina—cervical cancer	0.000845	0.00193	CbGeAlD
Crizotinib—JAK2—mammalian vulva—cervical cancer	0.000844	0.00193	CbGeAlD
Crizotinib—MAP3K3—endometrium—cervical cancer	0.000841	0.00192	CbGeAlD
Crizotinib—MAP4K5—endometrium—cervical cancer	0.000841	0.00192	CbGeAlD
Crizotinib—TEK—endometrium—cervical cancer	0.000841	0.00192	CbGeAlD
Crizotinib—EPHA2—mammalian vulva—cervical cancer	0.000834	0.00191	CbGeAlD
Crizotinib—SRC—epithelium—cervical cancer	0.000833	0.00191	CbGeAlD
Crizotinib—EPHA4—female reproductive system—cervical cancer	0.000833	0.00191	CbGeAlD
Crizotinib—ABL2—female gonad—cervical cancer	0.000828	0.0019	CbGeAlD
Crizotinib—SRC—uterine cervix—cervical cancer	0.000826	0.00189	CbGeAlD
Crizotinib—ABL2—vagina—cervical cancer	0.000823	0.00188	CbGeAlD
Crizotinib—BMP2K—female gonad—cervical cancer	0.000818	0.00187	CbGeAlD
Crizotinib—YES1—decidua—cervical cancer	0.000818	0.00187	CbGeAlD
Crizotinib—MAP3K2—female reproductive system—cervical cancer	0.000816	0.00187	CbGeAlD
Crizotinib—SLK—uterus—cervical cancer	0.000815	0.00187	CbGeAlD
Crizotinib—MAP3K3—mammalian vulva—cervical cancer	0.000813	0.00186	CbGeAlD
Crizotinib—MAP4K5—mammalian vulva—cervical cancer	0.000813	0.00186	CbGeAlD
Crizotinib—BMP2K—vagina—cervical cancer	0.000813	0.00186	CbGeAlD
Crizotinib—STK10—decidua—cervical cancer	0.000811	0.00186	CbGeAlD
Crizotinib—EPHB4—uterus—cervical cancer	0.00081	0.00185	CbGeAlD
Crizotinib—TAOK3—decidua—cervical cancer	0.000807	0.00185	CbGeAlD
Crizotinib—EPHB6—endometrium—cervical cancer	0.000803	0.00184	CbGeAlD
Crizotinib—YES1—renal system—cervical cancer	0.000803	0.00184	CbGeAlD
Crizotinib—MET—lymph node—cervical cancer	0.000802	0.00184	CbGeAlD
Crizotinib—PTK2—female reproductive system—cervical cancer	0.0008	0.00183	CbGeAlD
Crizotinib—TBK1—female reproductive system—cervical cancer	0.0008	0.00183	CbGeAlD
Crizotinib—STK10—renal system—cervical cancer	0.000796	0.00182	CbGeAlD
Crizotinib—TYK2—female reproductive system—cervical cancer	0.000794	0.00182	CbGeAlD
Crizotinib—TAOK3—renal system—cervical cancer	0.000793	0.00181	CbGeAlD
Crizotinib—PTK2B—female gonad—cervical cancer	0.00079	0.00181	CbGeAlD
Crizotinib—SRC—decidua—cervical cancer	0.000787	0.0018	CbGeAlD
Crizotinib—PTK2B—vagina—cervical cancer	0.000785	0.0018	CbGeAlD
Crizotinib—IRAK1—female reproductive system—cervical cancer	0.000784	0.00179	CbGeAlD
Crizotinib—RIPK2—female gonad—cervical cancer	0.000784	0.00179	CbGeAlD
Crizotinib—RIPK2—vagina—cervical cancer	0.000779	0.00178	CbGeAlD
Crizotinib—EPHB6—mammalian vulva—cervical cancer	0.000777	0.00178	CbGeAlD
Crizotinib—YES1—endometrium—cervical cancer	0.000776	0.00178	CbGeAlD
Crizotinib—CDK7—lymph node—cervical cancer	0.000776	0.00178	CbGeAlD
Crizotinib—MAP4K5—uterus—cervical cancer	0.000775	0.00177	CbGeAlD
Crizotinib—TEK—uterus—cervical cancer	0.000775	0.00177	CbGeAlD
Crizotinib—SRC—renal system—cervical cancer	0.000773	0.00177	CbGeAlD
Crizotinib—TAOK2—lymph node—cervical cancer	0.000769	0.00176	CbGeAlD
Crizotinib—RPS6KB1—female reproductive system—cervical cancer	0.000769	0.00176	CbGeAlD
Crizotinib—TAOK3—endometrium—cervical cancer	0.000766	0.00175	CbGeAlD
Crizotinib—FGR—female reproductive system—cervical cancer	0.000765	0.00175	CbGeAlD
Crizotinib—AXL—female reproductive system—cervical cancer	0.000761	0.00174	CbGeAlD
Crizotinib—EPHA4—female gonad—cervical cancer	0.000758	0.00173	CbGeAlD
Crizotinib—EPHA4—vagina—cervical cancer	0.000753	0.00172	CbGeAlD
Crizotinib—YES1—mammalian vulva—cervical cancer	0.000751	0.00172	CbGeAlD
Crizotinib—STK10—mammalian vulva—cervical cancer	0.000744	0.0017	CbGeAlD
Crizotinib—MAP3K2—female gonad—cervical cancer	0.000743	0.0017	CbGeAlD
Crizotinib—TAOK3—mammalian vulva—cervical cancer	0.000741	0.0017	CbGeAlD
Crizotinib—CSF1R—uterine cervix—cervical cancer	0.000741	0.0017	CbGeAlD
Crizotinib—EPHA3—lymph node—cervical cancer	0.000741	0.0017	CbGeAlD
Crizotinib—ACVR1B—lymph node—cervical cancer	0.000741	0.0017	CbGeAlD
Crizotinib—EPHB4—female reproductive system—cervical cancer	0.000728	0.00167	CbGeAlD
Crizotinib—TBK1—female gonad—cervical cancer	0.000728	0.00167	CbGeAlD
Crizotinib—PTK2—female gonad—cervical cancer	0.000728	0.00167	CbGeAlD
Crizotinib—PTK2—vagina—cervical cancer	0.000723	0.00166	CbGeAlD
Crizotinib—TBK1—vagina—cervical cancer	0.000723	0.00166	CbGeAlD
Crizotinib—TYK2—female gonad—cervical cancer	0.000723	0.00165	CbGeAlD
Crizotinib—JAK2—female reproductive system—cervical cancer	0.000723	0.00165	CbGeAlD
Crizotinib—TYK2—vagina—cervical cancer	0.000718	0.00164	CbGeAlD
Crizotinib—YES1—uterus—cervical cancer	0.000715	0.00164	CbGeAlD
Crizotinib—EPHA2—female reproductive system—cervical cancer	0.000714	0.00163	CbGeAlD
Crizotinib—IRAK1—female gonad—cervical cancer	0.000713	0.00163	CbGeAlD
Crizotinib—STK10—uterus—cervical cancer	0.000709	0.00162	CbGeAlD
Crizotinib—JAK3—lymph node—cervical cancer	0.000707	0.00162	CbGeAlD
Crizotinib—CSF1R—decidua—cervical cancer	0.000706	0.00162	CbGeAlD
Crizotinib—TAOK3—uterus—cervical cancer	0.000706	0.00162	CbGeAlD
Crizotinib—DCLK1—lymph node—cervical cancer	0.000703	0.00161	CbGeAlD
Crizotinib—RPS6KB1—female gonad—cervical cancer	0.0007	0.0016	CbGeAlD
Crizotinib—PLK4—lymph node—cervical cancer	0.000698	0.0016	CbGeAlD
Crizotinib—MAP4K5—female reproductive system—cervical cancer	0.000696	0.00159	CbGeAlD
Crizotinib—MAP3K3—female reproductive system—cervical cancer	0.000696	0.00159	CbGeAlD
Crizotinib—TEK—female reproductive system—cervical cancer	0.000696	0.00159	CbGeAlD
Crizotinib—RPS6KB1—vagina—cervical cancer	0.000696	0.00159	CbGeAlD
Crizotinib—FGR—female gonad—cervical cancer	0.000696	0.00159	CbGeAlD
Crizotinib—LCK—female gonad—cervical cancer	0.000696	0.00159	CbGeAlD
Crizotinib—STK4—lymph node—cervical cancer	0.000694	0.00159	CbGeAlD
Crizotinib—AXL—female gonad—cervical cancer	0.000693	0.00159	CbGeAlD
Crizotinib—FGR—vagina—cervical cancer	0.000691	0.00158	CbGeAlD
Crizotinib—LCK—vagina—cervical cancer	0.000691	0.00158	CbGeAlD
Crizotinib—AXL—vagina—cervical cancer	0.000689	0.00158	CbGeAlD
Crizotinib—CSF1R—endometrium—cervical cancer	0.000671	0.00153	CbGeAlD
Crizotinib—SLK—female gonad—cervical cancer	0.000667	0.00153	CbGeAlD
Crizotinib—SLK—vagina—cervical cancer	0.000663	0.00152	CbGeAlD
Crizotinib—EPHB4—female gonad—cervical cancer	0.000662	0.00152	CbGeAlD
Crizotinib—EPHB4—vagina—cervical cancer	0.000658	0.00151	CbGeAlD
Crizotinib—JAK2—female gonad—cervical cancer	0.000658	0.00151	CbGeAlD
Crizotinib—ALK—lymph node—cervical cancer	0.000656	0.0015	CbGeAlD
Crizotinib—FER—lymph node—cervical cancer	0.000656	0.0015	CbGeAlD
Crizotinib—JAK2—vagina—cervical cancer	0.000654	0.0015	CbGeAlD
Crizotinib—EPHA2—female gonad—cervical cancer	0.00065	0.00149	CbGeAlD
Crizotinib—TNK1—lymph node—cervical cancer	0.000649	0.00149	CbGeAlD
Crizotinib—CSF1R—mammalian vulva—cervical cancer	0.000649	0.00148	CbGeAlD
Crizotinib—EPHA2—vagina—cervical cancer	0.000646	0.00148	CbGeAlD
Crizotinib—YES1—female reproductive system—cervical cancer	0.000643	0.00147	CbGeAlD
Crizotinib—BMPR1B—lymph node—cervical cancer	0.000643	0.00147	CbGeAlD
Crizotinib—MAP4K1—lymph node—cervical cancer	0.000643	0.00147	CbGeAlD
Crizotinib—STK10—female reproductive system—cervical cancer	0.000637	0.00146	CbGeAlD
Crizotinib—TAOK3—female reproductive system—cervical cancer	0.000635	0.00145	CbGeAlD
Crizotinib—MAP4K5—female gonad—cervical cancer	0.000634	0.00145	CbGeAlD
Crizotinib—TEK—female gonad—cervical cancer	0.000634	0.00145	CbGeAlD
Crizotinib—MAP3K3—female gonad—cervical cancer	0.000634	0.00145	CbGeAlD
Crizotinib—TNK2—lymph node—cervical cancer	0.00063	0.00144	CbGeAlD
Crizotinib—IGF1R—lymph node—cervical cancer	0.00063	0.00144	CbGeAlD
Crizotinib—MAP3K3—vagina—cervical cancer	0.00063	0.00144	CbGeAlD
Crizotinib—MAP4K5—vagina—cervical cancer	0.00063	0.00144	CbGeAlD
Crizotinib—MAP4K2—lymph node—cervical cancer	0.000621	0.00142	CbGeAlD
Crizotinib—SRC—female reproductive system—cervical cancer	0.000619	0.00142	CbGeAlD
Crizotinib—CSF1R—uterus—cervical cancer	0.000618	0.00141	CbGeAlD
Crizotinib—TIE1—lymph node—cervical cancer	0.000613	0.0014	CbGeAlD
Crizotinib—STK3—lymph node—cervical cancer	0.000613	0.0014	CbGeAlD
Crizotinib—EPHB6—female gonad—cervical cancer	0.000606	0.00139	CbGeAlD
Crizotinib—EPHB6—vagina—cervical cancer	0.000602	0.00138	CbGeAlD
Crizotinib—AURKA—lymph node—cervical cancer	0.000597	0.00137	CbGeAlD
Crizotinib—TESK1—lymph node—cervical cancer	0.000593	0.00136	CbGeAlD
Crizotinib—ABL1—uterine cervix—cervical cancer	0.000586	0.00134	CbGeAlD
Crizotinib—YES1—female gonad—cervical cancer	0.000585	0.00134	CbGeAlD
Crizotinib—YES1—vagina—cervical cancer	0.000582	0.00133	CbGeAlD
Crizotinib—STK10—female gonad—cervical cancer	0.00058	0.00133	CbGeAlD
Crizotinib—TAOK3—female gonad—cervical cancer	0.000578	0.00132	CbGeAlD
Crizotinib—STK10—vagina—cervical cancer	0.000576	0.00132	CbGeAlD
Crizotinib—MERTK—lymph node—cervical cancer	0.000576	0.00132	CbGeAlD
Crizotinib—TAOK3—vagina—cervical cancer	0.000574	0.00131	CbGeAlD
Crizotinib—LIMK2—lymph node—cervical cancer	0.000564	0.00129	CbGeAlD
Crizotinib—SRC—female gonad—cervical cancer	0.000563	0.00129	CbGeAlD
Crizotinib—NUAK2—lymph node—cervical cancer	0.000562	0.00129	CbGeAlD
Crizotinib—ABL1—decidua—cervical cancer	0.000558	0.00128	CbGeAlD
Crizotinib—ACVR1—lymph node—cervical cancer	0.000558	0.00128	CbGeAlD
Crizotinib—FLT3—lymph node—cervical cancer	0.000558	0.00128	CbGeAlD
Crizotinib—MAP3K12—lymph node—cervical cancer	0.000558	0.00128	CbGeAlD
Crizotinib—CSF1R—female reproductive system—cervical cancer	0.000556	0.00127	CbGeAlD
Crizotinib—ABL1—renal system—cervical cancer	0.000548	0.00126	CbGeAlD
Crizotinib—STK35—lymph node—cervical cancer	0.000546	0.00125	CbGeAlD
Crizotinib—ABL2—lymph node—cervical cancer	0.000533	0.00122	CbGeAlD
Crizotinib—ABL1—endometrium—cervical cancer	0.00053	0.00121	CbGeAlD
Crizotinib—BMP2K—lymph node—cervical cancer	0.000526	0.0012	CbGeAlD
Crizotinib—ABL1—mammalian vulva—cervical cancer	0.000513	0.00117	CbGeAlD
Crizotinib—PTK2B—lymph node—cervical cancer	0.000508	0.00116	CbGeAlD
Crizotinib—CSF1R—female gonad—cervical cancer	0.000505	0.00116	CbGeAlD
Crizotinib—RIPK2—lymph node—cervical cancer	0.000504	0.00115	CbGeAlD
Crizotinib—CSF1R—vagina—cervical cancer	0.000502	0.00115	CbGeAlD
Crizotinib—ABL1—uterus—cervical cancer	0.000488	0.00112	CbGeAlD
Crizotinib—EPHA4—lymph node—cervical cancer	0.000487	0.00111	CbGeAlD
Crizotinib—MAP3K2—lymph node—cervical cancer	0.000478	0.00109	CbGeAlD
Crizotinib—PTK2—lymph node—cervical cancer	0.000468	0.00107	CbGeAlD
Crizotinib—TBK1—lymph node—cervical cancer	0.000468	0.00107	CbGeAlD
Crizotinib—TYK2—lymph node—cervical cancer	0.000465	0.00106	CbGeAlD
Crizotinib—IRAK1—lymph node—cervical cancer	0.000459	0.00105	CbGeAlD
Crizotinib—RPS6KB1—lymph node—cervical cancer	0.00045	0.00103	CbGeAlD
Crizotinib—FGR—lymph node—cervical cancer	0.000447	0.00102	CbGeAlD
Crizotinib—LCK—lymph node—cervical cancer	0.000447	0.00102	CbGeAlD
Crizotinib—AXL—lymph node—cervical cancer	0.000445	0.00102	CbGeAlD
Crizotinib—ABL1—female reproductive system—cervical cancer	0.000439	0.00101	CbGeAlD
Crizotinib—SLK—lymph node—cervical cancer	0.000429	0.000982	CbGeAlD
Crizotinib—EPHB4—lymph node—cervical cancer	0.000426	0.000974	CbGeAlD
Crizotinib—JAK2—lymph node—cervical cancer	0.000423	0.000968	CbGeAlD
Crizotinib—EPHA2—lymph node—cervical cancer	0.000418	0.000956	CbGeAlD
Crizotinib—MAP4K5—lymph node—cervical cancer	0.000407	0.000933	CbGeAlD
Crizotinib—MAP3K3—lymph node—cervical cancer	0.000407	0.000933	CbGeAlD
Crizotinib—TEK—lymph node—cervical cancer	0.000407	0.000933	CbGeAlD
Crizotinib—ABL1—female gonad—cervical cancer	0.0004	0.000915	CbGeAlD
Crizotinib—ABL1—vagina—cervical cancer	0.000397	0.000909	CbGeAlD
Crizotinib—EPHB6—lymph node—cervical cancer	0.000389	0.000891	CbGeAlD
Crizotinib—YES1—lymph node—cervical cancer	0.000376	0.000861	CbGeAlD
Crizotinib—STK10—lymph node—cervical cancer	0.000373	0.000853	CbGeAlD
Crizotinib—TAOK3—lymph node—cervical cancer	0.000371	0.00085	CbGeAlD
Crizotinib—SRC—lymph node—cervical cancer	0.000362	0.000829	CbGeAlD
Crizotinib—CYP3A5—uterine cervix—cervical cancer	0.000343	0.000785	CbGeAlD
Crizotinib—CSF1R—lymph node—cervical cancer	0.000325	0.000744	CbGeAlD
Crizotinib—CYP3A5—renal system—cervical cancer	0.000321	0.000735	CbGeAlD
Crizotinib—ABL1—lymph node—cervical cancer	0.000257	0.000588	CbGeAlD
Crizotinib—CYP3A4—renal system—cervical cancer	0.000241	0.000551	CbGeAlD
Crizotinib—CYP3A5—female gonad—cervical cancer	0.000234	0.000535	CbGeAlD
Crizotinib—CYP3A5—vagina—cervical cancer	0.000232	0.000532	CbGeAlD
Crizotinib—CYP3A4—female reproductive system—cervical cancer	0.000193	0.000442	CbGeAlD
Crizotinib—ABCB1—epithelium—cervical cancer	0.000184	0.000421	CbGeAlD
Crizotinib—ABCB1—uterine cervix—cervical cancer	0.000182	0.000417	CbGeAlD
Crizotinib—ABCB1—decidua—cervical cancer	0.000174	0.000397	CbGeAlD
Crizotinib—ABCB1—renal system—cervical cancer	0.00017	0.00039	CbGeAlD
Crizotinib—ABCB1—endometrium—cervical cancer	0.000165	0.000377	CbGeAlD
Crizotinib—ABCB1—mammalian vulva—cervical cancer	0.000159	0.000365	CbGeAlD
Crizotinib—ABCB1—uterus—cervical cancer	0.000152	0.000348	CbGeAlD
Crizotinib—ABCB1—female reproductive system—cervical cancer	0.000137	0.000313	CbGeAlD
Crizotinib—ABCB1—female gonad—cervical cancer	0.000124	0.000284	CbGeAlD
Crizotinib—ABCB1—vagina—cervical cancer	0.000123	0.000283	CbGeAlD
Crizotinib—ABCB1—lymph node—cervical cancer	7.99e-05	0.000183	CbGeAlD
Crizotinib—ABL1—Developmental Biology—EGFR—cervical cancer	1.89e-05	4.31e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—CD4—cervical cancer	1.89e-05	4.31e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—MTOR—cervical cancer	1.88e-05	4.29e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—HLA-DQB1—cervical cancer	1.88e-05	4.29e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—EGFR—cervical cancer	1.88e-05	4.29e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—CD4—cervical cancer	1.88e-05	4.28e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—STAT3—cervical cancer	1.87e-05	4.27e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TERT—cervical cancer	1.87e-05	4.26e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—MTHFR—cervical cancer	1.87e-05	4.26e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—MTOR—cervical cancer	1.87e-05	4.26e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—STAT3—cervical cancer	1.86e-05	4.25e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—CD4—cervical cancer	1.86e-05	4.25e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—TERT—cervical cancer	1.86e-05	4.25e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—HES1—cervical cancer	1.86e-05	4.25e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—FGFR3—cervical cancer	1.85e-05	4.22e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—STAT3—cervical cancer	1.84e-05	4.19e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—STAT3—cervical cancer	1.83e-05	4.17e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NOTCH2—cervical cancer	1.82e-05	4.14e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—TP53—cervical cancer	1.81e-05	4.12e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—STAT3—cervical cancer	1.8e-05	4.12e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—STAT3—cervical cancer	1.79e-05	4.09e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—STAT3—cervical cancer	1.79e-05	4.08e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—EGFR—cervical cancer	1.78e-05	4.06e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TERT—cervical cancer	1.77e-05	4.04e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—MTOR—cervical cancer	1.77e-05	4.04e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CA9—cervical cancer	1.77e-05	4.03e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CD4—cervical cancer	1.77e-05	4.03e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD8A—cervical cancer	1.76e-05	4e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—MTOR—cervical cancer	1.75e-05	3.99e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	1.75e-05	3.98e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—CTNNB1—cervical cancer	1.74e-05	3.97e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—FGFR3—cervical cancer	1.74e-05	3.97e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—CTNNB1—cervical cancer	1.74e-05	3.96e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—MTOR—cervical cancer	1.73e-05	3.96e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—CD4—cervical cancer	1.73e-05	3.95e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TERT—cervical cancer	1.72e-05	3.93e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—MTOR—cervical cancer	1.72e-05	3.92e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CD4—cervical cancer	1.72e-05	3.91e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—FGFR3—cervical cancer	1.72e-05	3.91e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—FGFR3—cervical cancer	1.71e-05	3.9e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—EGFR—cervical cancer	1.7e-05	3.88e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—EGFR—cervical cancer	1.69e-05	3.86e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CASP8—cervical cancer	1.69e-05	3.86e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CASP8—cervical cancer	1.68e-05	3.84e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—EGFR—cervical cancer	1.68e-05	3.83e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—CTNNB1—cervical cancer	1.68e-05	3.83e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—EGFR—cervical cancer	1.67e-05	3.81e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—EGFR—cervical cancer	1.67e-05	3.81e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—MTOR—cervical cancer	1.67e-05	3.8e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—EGFR—cervical cancer	1.66e-05	3.79e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—CD4—cervical cancer	1.66e-05	3.79e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—CTNNB1—cervical cancer	1.66e-05	3.77e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—HES1—cervical cancer	1.65e-05	3.76e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—EGFR—cervical cancer	1.64e-05	3.74e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—MTHFR—cervical cancer	1.64e-05	3.73e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NOTCH1—cervical cancer	1.63e-05	3.73e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—TERT—cervical cancer	1.63e-05	3.72e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—EGFR—cervical cancer	1.63e-05	3.72e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—FGFR3—cervical cancer	1.63e-05	3.71e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—EGFR—cervical cancer	1.62e-05	3.7e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—FGFR3—cervical cancer	1.62e-05	3.7e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—EGFR—cervical cancer	1.61e-05	3.68e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NOTCH1—cervical cancer	1.61e-05	3.67e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—CASP3—cervical cancer	1.61e-05	3.67e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—NOTCH1—cervical cancer	1.61e-05	3.66e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HES1—cervical cancer	1.59e-05	3.63e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NOTCH2—cervical cancer	1.59e-05	3.63e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—MTOR—cervical cancer	1.59e-05	3.62e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—CD4—cervical cancer	1.58e-05	3.61e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CASP8—cervical cancer	1.58e-05	3.61e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—FGFR3—cervical cancer	1.58e-05	3.6e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—TP53—cervical cancer	1.58e-05	3.6e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—EGFR—cervical cancer	1.57e-05	3.58e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CTNNB1—cervical cancer	1.57e-05	3.58e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—TP53—cervical cancer	1.57e-05	3.57e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MTOR—cervical cancer	1.56e-05	3.56e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—TP53—cervical cancer	1.56e-05	3.55e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—CTNNB1—cervical cancer	1.55e-05	3.54e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—CTNNB1—cervical cancer	1.54e-05	3.51e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MTOR—cervical cancer	1.54e-05	3.51e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NOTCH1—cervical cancer	1.53e-05	3.48e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CTNNB1—cervical cancer	1.52e-05	3.48e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—STAT3—cervical cancer	1.52e-05	3.46e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—FGFR3—cervical cancer	1.5e-05	3.42e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HES1—cervical cancer	1.49e-05	3.4e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NOTCH1—cervical cancer	1.48e-05	3.38e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MTOR—cervical cancer	1.47e-05	3.36e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	1.47e-05	3.34e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—TP53—cervical cancer	1.47e-05	3.34e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—STAT3—cervical cancer	1.46e-05	3.34e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—MTHFR—cervical cancer	1.45e-05	3.3e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—TERT—cervical cancer	1.44e-05	3.29e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—STAT3—cervical cancer	1.44e-05	3.29e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—FGFR3—cervical cancer	1.44e-05	3.27e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CASP3—cervical cancer	1.43e-05	3.27e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—TP53—cervical cancer	1.43e-05	3.26e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MTOR—cervical cancer	1.43e-05	3.25e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CASP3—cervical cancer	1.41e-05	3.22e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOTCH2—cervical cancer	1.41e-05	3.21e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—CTNNB1—cervical cancer	1.41e-05	3.21e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—NOTCH1—cervical cancer	1.41e-05	3.21e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—TP53—cervical cancer	1.4e-05	3.19e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TERT—cervical cancer	1.39e-05	3.18e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—MTOR—cervical cancer	1.39e-05	3.17e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD4—cervical cancer	1.39e-05	3.17e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CASP8—cervical cancer	1.39e-05	3.16e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—MTOR—cervical cancer	1.39e-05	3.16e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD4—cervical cancer	1.38e-05	3.15e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CTNNB1—cervical cancer	1.38e-05	3.15e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—EGFR—cervical cancer	1.38e-05	3.15e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—EGFR—cervical cancer	1.38e-05	3.14e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—STAT3—cervical cancer	1.37e-05	3.12e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CTNNB1—cervical cancer	1.36e-05	3.11e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CASP3—cervical cancer	1.35e-05	3.09e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—STAT3—cervical cancer	1.35e-05	3.08e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—EGFR—cervical cancer	1.33e-05	3.03e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—STAT3—cervical cancer	1.33e-05	3.03e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—FGFR3—cervical cancer	1.33e-05	3.02e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—EGFR—cervical cancer	1.32e-05	3.01e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—EGFR—cervical cancer	1.32e-05	3.01e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CASP3—cervical cancer	1.31e-05	2.99e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—EGFR—cervical cancer	1.31e-05	2.99e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TERT—cervical cancer	1.3e-05	2.98e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CTNNB1—cervical cancer	1.3e-05	2.97e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HES1—cervical cancer	1.3e-05	2.97e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—MTOR—cervical cancer	1.3e-05	2.97e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD4—cervical cancer	1.3e-05	2.97e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TP53—cervical cancer	1.28e-05	2.93e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—FGFR3—cervical cancer	1.28e-05	2.92e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CTNNB1—cervical cancer	1.26e-05	2.88e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—NOTCH1—cervical cancer	1.24e-05	2.84e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—EGFR—cervical cancer	1.24e-05	2.84e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CTNNB1—cervical cancer	1.23e-05	2.81e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—EGFR—cervical cancer	1.23e-05	2.8e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CTNNB1—cervical cancer	1.23e-05	2.8e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CASP8—cervical cancer	1.23e-05	2.8e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—STAT3—cervical cancer	1.23e-05	2.8e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MTOR—cervical cancer	1.22e-05	2.79e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—EGFR—cervical cancer	1.22e-05	2.78e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—EGFR—cervical cancer	1.21e-05	2.75e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MTOR—cervical cancer	1.21e-05	2.75e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—STAT3—cervical cancer	1.21e-05	2.75e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—MTOR—cervical cancer	1.2e-05	2.74e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NOTCH1—cervical cancer	1.2e-05	2.74e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—CD4—cervical cancer	1.2e-05	2.74e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—FGFR3—cervical cancer	1.2e-05	2.73e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—STAT3—cervical cancer	1.19e-05	2.71e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—EGFR—cervical cancer	1.17e-05	2.67e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CTNNB1—cervical cancer	1.16e-05	2.63e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HES1—cervical cancer	1.15e-05	2.63e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MTOR—cervical cancer	1.15e-05	2.61e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TERT—cervical cancer	1.14e-05	2.61e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—MTOR—cervical cancer	1.14e-05	2.6e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD4—cervical cancer	1.14e-05	2.6e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—STAT3—cervical cancer	1.14e-05	2.59e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—cervical cancer	1.14e-05	2.59e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CASP3—cervical cancer	1.13e-05	2.57e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NOTCH1—cervical cancer	1.12e-05	2.56e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—EGFR—cervical cancer	1.11e-05	2.54e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MTOR—cervical cancer	1.11e-05	2.53e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CASP3—cervical cancer	1.11e-05	2.53e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—STAT3—cervical cancer	1.1e-05	2.51e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—EGFR—cervical cancer	1.1e-05	2.5e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CA9—cervical cancer	1.09e-05	2.49e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CTNNB1—cervical cancer	1.09e-05	2.47e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—EGFR—cervical cancer	1.08e-05	2.46e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—STAT3—cervical cancer	1.08e-05	2.45e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—STAT3—cervical cancer	1.07e-05	2.44e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CTNNB1—cervical cancer	1.07e-05	2.44e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—CTNNB1—cervical cancer	1.07e-05	2.43e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—MTOR—cervical cancer	1.05e-05	2.4e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CASP3—cervical cancer	1.05e-05	2.4e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CD4—cervical cancer	1.05e-05	2.4e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FGFR3—cervical cancer	1.05e-05	2.39e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—EGFR—cervical cancer	1.03e-05	2.36e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—cervical cancer	1.03e-05	2.35e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CASP3—cervical cancer	1.02e-05	2.33e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CTNNB1—cervical cancer	1.02e-05	2.31e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TERT—cervical cancer	1.01e-05	2.31e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CTNNB1—cervical cancer	1.01e-05	2.31e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—MTOR—cervical cancer	1.01e-05	2.3e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD4—cervical cancer	1.01e-05	2.3e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—STAT3—cervical cancer	1.01e-05	2.3e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EGFR—cervical cancer	1e-05	2.29e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—EGFR—cervical cancer	1e-05	2.28e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CTNNB1—cervical cancer	9.85e-06	2.25e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NOTCH1—cervical cancer	9.85e-06	2.25e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—EGFR—cervical cancer	9.78e-06	2.23e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EGFR—cervical cancer	9.73e-06	2.22e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—MTHFR—cervical cancer	9.51e-06	2.17e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—STAT3—cervical cancer	9.46e-06	2.16e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CTNNB1—cervical cancer	9.34e-06	2.13e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—STAT3—cervical cancer	9.33e-06	2.13e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—MTOR—cervical cancer	9.33e-06	2.13e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CD4—cervical cancer	9.31e-06	2.12e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—STAT3—cervical cancer	9.3e-06	2.12e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGFR3—cervical cancer	9.28e-06	2.12e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—cervical cancer	9.2e-06	2.1e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EGFR—cervical cancer	9.15e-06	2.09e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—cervical cancer	9.07e-06	2.07e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MTOR—cervical cancer	9e-06	2.05e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CTNNB1—cervical cancer	8.96e-06	2.04e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—STAT3—cervical cancer	8.85e-06	2.02e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—STAT3—cervical cancer	8.82e-06	2.01e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOTCH1—cervical cancer	8.72e-06	1.99e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—cervical cancer	8.68e-06	1.98e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EGFR—cervical cancer	8.6e-06	1.96e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—STAT3—cervical cancer	8.59e-06	1.96e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EGFR—cervical cancer	8.48e-06	1.93e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—EGFR—cervical cancer	8.45e-06	1.93e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MTOR—cervical cancer	8.42e-06	1.92e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—cervical cancer	8.41e-06	1.92e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CASP3—cervical cancer	8.28e-06	1.89e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CTNNB1—cervical cancer	8.27e-06	1.89e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—STAT3—cervical cancer	8.14e-06	1.86e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EGFR—cervical cancer	8.04e-06	1.83e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—EGFR—cervical cancer	8.02e-06	1.83e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CTNNB1—cervical cancer	7.98e-06	1.82e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—STAT3—cervical cancer	7.81e-06	1.78e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EGFR—cervical cancer	7.81e-06	1.78e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CASP3—cervical cancer	7.75e-06	1.77e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CTNNB1—cervical cancer	7.47e-06	1.7e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—EGFR—cervical cancer	7.4e-06	1.69e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MTOR—cervical cancer	7.38e-06	1.68e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—cervical cancer	7.22e-06	1.65e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—STAT3—cervical cancer	7.21e-06	1.64e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MTHFR—cervical cancer	7.18e-06	1.64e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—cervical cancer	7.12e-06	1.62e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—EGFR—cervical cancer	7.1e-06	1.62e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—STAT3—cervical cancer	6.96e-06	1.59e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CASP3—cervical cancer	6.79e-06	1.55e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—cervical cancer	6.75e-06	1.54e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—cervical cancer	6.56e-06	1.49e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—EGFR—cervical cancer	6.55e-06	1.49e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CTNNB1—cervical cancer	6.54e-06	1.49e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MTOR—cervical cancer	6.53e-06	1.49e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—STAT3—cervical cancer	6.51e-06	1.48e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EGFR—cervical cancer	6.32e-06	1.44e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CASP3—cervical cancer	6.01e-06	1.37e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EGFR—cervical cancer	5.92e-06	1.35e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CTNNB1—cervical cancer	5.79e-06	1.32e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—STAT3—cervical cancer	5.7e-06	1.3e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—cervical cancer	5.31e-06	1.21e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGFR—cervical cancer	5.18e-06	1.18e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—STAT3—cervical cancer	5.05e-06	1.15e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—cervical cancer	4.97e-06	1.13e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGFR—cervical cancer	4.59e-06	1.05e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MTHFR—cervical cancer	4.42e-06	1.01e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—cervical cancer	4.35e-06	9.92e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—cervical cancer	3.85e-06	8.78e-06	CbGpPWpGaD
